The New England journal of medicine, 2021-10, Vol.385 (15), p.1382-1392
- Dougan, Michael
- Nirula, Ajay
- Azizad, Masoud
- Mocherla, Bharat
- Gottlieb, Robert L
- Chen, Peter
- Hebert, Corey
- Perry, Russell
- Boscia, Joseph
- Heller, Barry
- Morris, Jason
- Crystal, Chad
- Igbinadolor, Awawu
- Huhn, Gregory
- Cardona, Jose
- Shawa, Imad
- Kumar, Princy
- Adams, Andrew C
- Van Naarden, Jacob
- Custer, Kenneth L
- Durante, Michael
- Oakley, Gerard
- Schade, Andrew E
- Holzer, Timothy R
- Ebert, Philip J
- Higgs, Richard E
- Kallewaard, Nicole L
- Sabo, Janelle
- Patel, Dipak R
- Dabora, Matan C
- Klekotka, Paul
- Shen, Lei
- Skovronsky, Daniel M
2021
Details
- Autor(en) / Beteiligte
- Dougan, Michael
- Nirula, Ajay
- Azizad, Masoud
- Mocherla, Bharat
- Gottlieb, Robert L
- Chen, Peter
- Hebert, Corey
- Perry, Russell
- Boscia, Joseph
- Heller, Barry
- Morris, Jason
- Crystal, Chad
- Igbinadolor, Awawu
- Huhn, Gregory
- Cardona, Jose
- Shawa, Imad
- Kumar, Princy
- Adams, Andrew C
- Van Naarden, Jacob
- Custer, Kenneth L
- Durante, Michael
- Oakley, Gerard
- Schade, Andrew E
- Holzer, Timothy R
- Ebert, Philip J
- Higgs, Richard E
- Kallewaard, Nicole L
- Sabo, Janelle
- Patel, Dipak R
- Dabora, Matan C
- Klekotka, Paul
- Shen, Lei
- Skovronsky, Daniel M
- Titel
- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
- Ist Teil von
- The New England journal of medicine, 2021-10, Vol.385 (15), p.1382-1392
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- In a phase 3 trial involving 1035 outpatients who were at increased risk for severe Covid-19, those who received two monoclonal antibodies targeting SARS-CoV-2 had a significant reduction in the viral load and a significantly lower incidence of progression to severe illness than those who received placebo.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2102685Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8314785
- Format
- –
- Schlagworte
- Adolescent, Adult, Age, Aged, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Cardiovascular disease, Child, Coronavirus, Coronaviruses, COVID-19, COVID-19 - drug therapy, COVID-19 - ethnology, COVID-19 - virology, COVID-19 vaccines, Death, Diabetes, Double-Blind Method, Drug Therapy, Combination, Female, Hospitalization, Hospitalization - statistics & numerical data, Humans, Hypertension, Immunity (passive), Immunotherapy, Infectious Disease, Infusions, Intravenous, International organizations, Intravenous administration, Kaplan-Meier Estimate, Kidney diseases, Male, Medical research, Middle Aged, Monoclonal antibodies, Original, Ostomy, Patient Acuity, Patients, Placebos, Respiratory diseases, Risk Factors, SARS-CoV-2 - isolation & purification, Severe acute respiratory syndrome coronavirus 2, Teenagers, Testing, Viral Load - drug effects, Young Adult